|
interprofessional education |
47 |
|
social interaction anxiety |
40 |
|
covid-19 |
35 |
|
partnership model |
28 |
|
heart failure |
14 |
|
sars-cov-2 |
14 |
|
construct validation |
12 |
|
achievement emotions |
11 |
|
cluster analysis |
11 |
|
healthcare students |
11 |
|
interprofessional collaboration |
11 |
|
person-centred analysis |
11 |
|
anosmia |
10 |
|
olfactory dysfunction |
10 |
|
smell impairment |
10 |
|
atrial fibrillation |
9 |
|
collaboration perception |
9 |
|
extracorporeal membrane oxygenation |
9 |
|
health professions education |
9 |
|
interprofessional identity |
9 |
|
medical education |
9 |
|
acute infection |
8 |
|
cardiac function |
8 |
|
cirrhosis |
8 |
|
convalescent |
8 |
|
dendritic cell |
8 |
|
early |
8 |
|
high-risk |
8 |
|
intensive care unit |
8 |
|
interferon beta-1b |
8 |
|
intracranial hemorrhages |
8 |
|
liver transplantation |
8 |
|
remdesivir |
8 |
|
mortality |
7 |
|
transthoracic echocardiography |
7 |
|
extracorporeal membrane oxygenation (ecmo) |
6 |
|
aerosol |
5 |
|
aerosol box |
5 |
|
antibodies, neutralizing - blood |
5 |
|
cannulation |
5 |
|
cardiology |
5 |
|
chinese |
5 |
|
clinical characteristics |
5 |
|
coronary heart disease |
5 |
|
coronary intervention |
5 |
|
drug escalation |
5 |
|
dual lumen cannula |
5 |
|
female |
5 |
|
immunotherapy - methods |
5 |
|
infection |
5 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
5 |
|
influenza, human - mortality - therapy - virology |
5 |
|
ischaemic heart disease |
5 |
|
manikin, intubation tent |
5 |
|
outcomes |
5 |
|
percutaneous coronary intervention |
5 |
|
plasma - immunology |
5 |
|
rapid sequence intubation |
5 |
|
telemonitoring |
5 |
|
absorb |
4 |
|
afterload |
4 |
|
left ventricular systolic function |
4 |
|
adolescent |
3 |
|
adult |
3 |
|
age distribution |
3 |
|
anti-bacterial agents |
3 |
|
aspergillosis - immunology - microbiology |
3 |
|
attitude to health |
3 |
|
bacteremia - diagnosis - drug therapy - epidemiology |
3 |
|
beta-lactamases - metabolism |
3 |
|
cardiac arrest |
3 |
|
cardiogenic shock |
3 |
|
cardiopulmonary resuscitation |
3 |
|
case volume |
3 |
|
case-control studies |
3 |
|
china - epidemiology |
3 |
|
cohort studies |
3 |
|
confidence intervals |
3 |
|
cross-sectional study |
3 |
|
drug therapy, combination - therapeutic use |
3 |
|
ecmo |
3 |
|
epidemiology |
3 |
|
escherichia coli - enzymology - isolation & purification |
3 |
|
escherichia coli infections - diagnosis - drug therapy - epidemiology |
3 |
|
follow-up studies |
3 |
|
gastric acid |
3 |
|
gastric cancer |
3 |
|
health policy |
3 |
|
health systems |
3 |
|
hemoglobin |
3 |
|
humans |
3 |
|
immunity, active |
3 |
|
immunity, natural |
3 |
|
incidence |
3 |
|
intensive care unit (icu) |
3 |
|
length of stay (los) |
3 |
|
lung diseases, fungal - immunology - microbiology |
3 |
|
male |
3 |
|
microbial sensitivity tests |
3 |
|
multivariate analysis |
3 |
|
myocardial strain |
3 |
|
neurologic outcomes |
3 |
|
outcome |
3 |
|
pcrto |
3 |
|
pneumocystis - immunology |
3 |
|
prediction |
3 |
|
probability |
3 |
|
proton pump inhibition |
3 |
|
red blood cell transfusion |
3 |
|
retrograde |
3 |
|
review |
3 |
|
risk factors |
3 |
|
sepsis |
3 |
|
septic shock |
3 |
|
sex distribution |
3 |
|
speckle tracking echocardiography |
3 |
|
survival rate |
3 |
|
target blood flow |
3 |
|
treatment outcome |
3 |
|
veno-arterial ecmo |
3 |
|
weaning |
3 |
|
acute kidney injury |
2 |
|
all-cause mortality |
2 |
|
analgesia |
2 |
|
anesthesia |
2 |
|
antidiabetic agent |
2 |
|
apache iv |
2 |
|
bare-metal stent |
2 |
|
benchmarking |
2 |
|
biguanide |
2 |
|
bioresorbable vascular scaffold |
2 |
|
bioresorbable vascular scaffold; |
2 |
|
bridging |
2 |
|
cardiovascular mortality |
2 |
|
citrate accumulation |
2 |
|
credentialing |
2 |
|
crisis resource management |
2 |
|
debriefing |
2 |
|
diabetes |
2 |
|
dipeptidyl peptidase-4 inhibitor |
2 |
|
double lumen cannula |
2 |
|
dpp‐4 inhibitor |
2 |
|
drug-eluting stent |
2 |
|
ecmo crisis |
2 |
|
ecpr |
2 |
|
extracorporeal life support (ecls) |
2 |
|
global longitudinal strain |
2 |
|
hematology |
2 |
|
high-fidelity simulation |
2 |
|
hong kong |
2 |
|
human learning |
2 |
|
intensive care |
2 |
|
lactate kinetics |
2 |
|
lactic acidosis |
2 |
|
laundry |
2 |
|
linens |
2 |
|
medicine & public health |
2 |
|
metformin |
2 |
|
metformin-associated lactic acidosis |
2 |
|
myocardial infarction |
2 |
|
non-insulin-dependent diabetes - treatment |
2 |
|
oncology |
2 |
|
outbreak |
2 |
|
pharmacology |
2 |
|
poisoning |
2 |
|
radial artery catheter |
2 |
|
refractory cardiac arrest |
2 |
|
regional citrate anticoagulation |
2 |
|
rhizopus microsporus |
2 |
|
sepsis-induced myocardial dysfunction |
2 |
|
septic cardiomyopathy |
2 |
|
serum citrate level |
2 |
|
serum lactate level |
2 |
|
sglt2 inhibitor |
2 |
|
simulation |
2 |
|
sodium-glucose cotransporter 2 inhibitor |
2 |
|
speckle tracking imaging |
2 |
|
standard mortality ratio |
2 |
|
strain |
2 |
|
stroke |
2 |
|
tolerability |
2 |
|
toxicology |
2 |
|
type 2 diabetes |
2 |
|
venoarterial ecls |
2 |
|
venoarterial extracorporeal membrane oxygenation (va ecmo) |
2 |
|
zygomycosis |
2 |
|
28-day mortality |
1 |
|
90-day mortality |
1 |
|
adult intensive & critical care |
1 |
|
aged |
1 |
|
antithrombotic agents |
1 |
|
ards |
1 |
|
asia-pacific |
1 |
|
aspirin hypersensitivity |
1 |
|
brain ischemia |
1 |
|
buttock ischemia |
1 |
|
case report |
1 |
|
cohort analysis |
1 |
|
cohort study |
1 |
|
coronary artery disease |
1 |
|
coronavirus |
1 |
|
crisis management |
1 |
|
critical care |
1 |
|
critical illness |
1 |
|
critically ill patients |
1 |
|
ddavp |
1 |
|
delayed emergence from anesthesia |
1 |
|
direct oral anticoagulant |
1 |
|
disease association |
1 |
|
doripenem |
1 |
|
early ambulation |
1 |
|
electronic health record |
1 |
|
endothelial progenitor cell capture stents |
1 |
|
extracorporeal membrane oxygenation complication |
1 |
|
feasibility study |
1 |
|
glim |
1 |
|
gluteal necrosis |
1 |
|
hemofiltration |
1 |
|
hyponatremia |
1 |
|
icu |
1 |
|
impella |
1 |
|
infection control |
1 |
|
intra-aortic balloon pump (iabp) |
1 |
|
left atrial appendage occlusion |
1 |
|
lung protection ventilation: pressure goal |
1 |
|
major bleeding |
1 |
|
malnutrition |
1 |
|
mechanical circulatory support (mcs) |
1 |
|
medical resource utilisation |
1 |
|
meta-analysis |
1 |
|
neostigmine: dose rationale |
1 |
|
neuromuscular block: assessment |
1 |
|
nutric |
1 |
|
obesity |
1 |
|
obesity paradox |
1 |
|
overweight |
1 |
|
pandemic |
1 |
|
paradoxical embolism |
1 |
|
patent foramen ovale |
1 |
|
patient care |
1 |
|
physical therapy |
1 |
|
preparedness |
1 |
|
pressure‐controlled ventilation |
1 |
|
protein |
1 |
|
quality measures |
1 |
|
renal replacement therapy |
1 |
|
respiratory infections |
1 |
|
sars |
1 |
|
surgery |
1 |
|
tandemheart (th) |
1 |
|
volume‐controlled ventilation |
1 |
